Don't be late! Timely identification of cognitive impairment in people with multiple sclerosis: a study protocol.

"Declarations Ethics approval and consent to participateThe Medical Ethical Committee of the Amsterdam UMC, Vrije Universiteit Amsterdam has reviewed and approved this study (METC 2021.0707, protocol version 2, 4 May 2022). Any future substantial changes to the study protocol will undergo review and approval by the METC. Written informed consent is obtained from all participants upon enrolment in the study. Consent for publicationNot applicable. Competing interestsPauline T. Waskowiak has no competing interests regarding publication.Brigit A. de Jong has no competing interests regarding publication.Bernard M.J. Uitdehaag has received research support and/or consultancy fees from Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, Teva and Immunic Therapeutics.Shalina R.D. Saddal has no competing interests regarding publication.Jip Aarts has no competing interests regarding publication.Aïda A.M. Roovers has no competing interests regarding publication.Pim van Oirschot is employed by Sherpa BV.Vincent de Groot has no competing interests regarding publication.Frederieke G. Schaafsma has no competing interests regarding publication.Karin van der Hiele has no competing interests regarding publication.Marit F.L. Ruitenberg has no competing interests regarding publication.Menno M. Schoonheim serves on the editorial board of Neurology, Multiple Sclerosis Journal and Frontiers in Neurology, receives research support from the Dutch MS Research Foundation, Eurostars-EUREKA, ARSEP, Amsterdam Neuroscience, MAGNIMS and ZonMW (Vidi grant, project number 09150172010056) and has served as a consultant for or received research support from Atara Biotherapeutics, Biogen, Celgene/Bristol Meyers Squibb, EIP, Sanofi, MedDay and Merck.Guy A.M. Widdershoven has no competing interests regarding publication.Sabina van der Veen has no competing interests regarding publication.Esther C.F. Schippers has no competing interests regarding publication.Martin Klein has no competing interests regarding publication.Hanneke E. Hulst is an editor of the Multiple Sclerosis Journal controversies sections, receives research support from the Dutch MS Research Foundation and the Dutch Research Council. She has served as a consultant for or received research support from Atara Biotherapeutics, Biogen, Novartis, Celgene/Bristol Meyers Squibb, Sanofi Genzyme, MedDay and Merck BV. Competing interests Pauline T. Waskowiak has no competing interests regarding publication. Brigit A. de Jong has no competing interests regarding publication. Bernard M.J. Uitdehaag has received research support and/or consultancy fees from Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, Teva and Immunic Therapeutics. Shalina R.D. Saddal has no competing interests regarding publication. Jip Aarts has no competing interests regarding publication. Aïda A.M. Roovers has no competing interests regarding publication. Pim van Oirschot is employed by Sherpa BV. Vincent de Groot has no competing interests regarding publication. Frederieke G. Schaafsma has no competing interests regarding publication. Karin van der Hiele has no competing interests regarding publication. Marit F.L. Ruitenberg has no competing interests regarding publication. Menno M. Schoonheim serves on the editorial board of Neurology, Multiple Sclerosis Journal and Frontiers in Neurology, receives research support from the Dutch MS Research Foundation, Eurostars-EUREKA, ARSEP, Amsterdam Neuroscience, MAGNIMS and ZonMW (Vidi grant, project number 09150172010056) and has served as a consultant for or received research support from Atara Biotherapeutics, Biogen, Celgene/Bristol Meyers Squibb, EIP, Sanofi, MedDay and Merck. Guy A.M. Widdershoven has no competing interests regarding publication. Sabina van der Veen has no competing interests regarding publication. Esther C.F. Schippers has no competing interests regarding publication. Martin Klein has no competing interests regarding publication. Hanneke E. Hulst is an editor of the Multiple Sclerosis Journal controversies sections, receives research support from the Dutch MS Research Foundation and the Dutch Research Council. She has served as a consultant for or received research support from Atara Biotherapeutics, Biogen, Novartis, Celgene/Bristol Meyers Squibb, Sanofi Genzyme, MedDay and Merck BV."

"Funding This study is peer-reviewed and funded by the Dutch Research Council (NWO) as part of the Dutch National Research Agenda (NWA), file number NWA.1292.19.064. The funder does not have role in the design of the study and collection, analysis, and interpretation of the data and in writing the manuscript."